Huadong Medicine

Huadong Medicine Co., Ltd. (Stock Code: 000963) was established in 1993, with its headquarters located in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. The company's business covers the entire pharmaceutical industry chain, led by pharmaceutical manufacturing, while also expanding into pharmaceutical commerce and medical aesthetics. It has developed into a large comprehensive pharmaceutical listed company that integrates pharmaceutical research and development, production, and distribution. The company consistently adheres to the corporate philosophy of "research-based and patient-centered," striving to become an internationally renowned strong pharmaceutical enterprise driven by scientific innovation. The company has over 10,000 employees, with operating revenue reaching 33.683 billion yuan in 2020 and net profit attributable to shareholders amounting to 2.82 billion yuan. The company’s return on equity (ROE) has exceeded 20% for 14 consecutive years. Huadong Medicine focuses on R&D, production, and sales in specialized fields, chronic disease medications, and special drugs, covering core product pipelines primarily in areas such as chronic kidney disease, transplantation immunology, endocrinology, and digestive system treatments. It holds multiple first-line clinical drugs with market advantages in China, simultaneously focusing on innovative drug R&D and high-tech barrier generic drugs in three core therapeutic areas—oncology, endocrinology, and autoimmune diseases—through self-development, external introduction, and project collaboration. Pharmaceutical sales channels have covered more than ten thousand large and medium-sized hospitals across China. The company continuously carries out international registration and certification of products, being the first in China to have Acarbose and Pantoprazole formulations pass U.S. FDA certification. In recent years, the company has consistently invested over 1 billion yuan annually in R&D, winning the National Science and Technology Progress Award (second prize) three times and the 2017 Zhejiang Provincial Government Quality Award. It has built a globally collaborative R&D ecosystem centered around Sinopharm East China, forming a complete pharmaceutical manufacturing system that is domestically leading and internationally oriented.